Rosemont Pharmaceuticals Ltd has launched Clonazepam 0.5mg/5ml and 2mg/5ml oral solutions. It is indicated for all clinical forms of epileptic disease and seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements.

Please refer to the links below for the New SPC for new product Clonazepam oral solutions.